|
Neonatal Intensive Care Drug Manual
|
| bet | 279/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Ibuprofen
Revision Date : 27 April 2021
|
Approved: TC, KOH
|
Alert
|
Pedea is currently the only registered product with Therapeutic Goods Administration (TGA) for closure of patent ductus arteriosus in preterm infants <34 weeks gestation.
Neoprofen is not currently registered with TGA. It is available for use via the Special Access Scheme (SAS).
Caldolor is registered for fever reduction and postoperative pain in adults.
|
Indication
|
Patent ductus arteriosus.
|
Action
|
Prostaglandin inhibitor. Prostaglandins are important in maintaining ductal patency in utero.
|
Drug type
|
Non-steroidal anti-inflammatory drug (NSAID).
|
Trade name
|
Intravenous: Pedea (ibuprofen sodium), Neoprofen (ibuprofen lysine). Caldolor (ibuprofen arginine),
Oral: FenPaed, Advil, Bugesic, Chemist’s Own, Dimetapp, iProfen, Nurofen
|
Presentation
|
IV:
Pedea (ibuprofen sodium) 10 mg in 2 mL vial.
Neoprofen (ibuprofen lysine) 20 mg in 2 mL vial.
Caldolor (ibuprofen arginine) 800 mg in 8 mL vial.
Oral: 100 mg/5 mL suspension
|
|
|
| |
